QuantAnts Machines Discover Biomarkers for RAS Signaling Activation and Design sgRNAs for CRISPR to Target Complex CD9, CD34, and CD74

The document introduces a quantum algorithm called QuantAnts machines for identifying biomarkers in oncology. This machine intelligence allows for the sampling of biomarker-verse for targeted RAS signaling activation, revealing combinations of biomarkers with therapeutic applications. The QuantAnts for Clinical Oncology model, ASCO(ant-4), identifies the complex CD9, CD34, and CD74 as targets for the RAS pathway in various cancer phenotypes. The model is further generalized for genetic code designs (QuantAnts-CRISPR), enabling optimized sgRNA for CRISPR-Cas9 to target the complex CD9, CD34, and CD74 simultaneously. The sgRNA designs are optimized by reversing mutation processes over the targeted complex.